What does the new research on Vitamin B12-based therapy for brain cancer reveal?
Researchers have developed a modified vitamin B12 analogue called NO-Cbl that can cross the blood-brain barrier to target glioblastoma cells. This preclinical study uses the molecule to deliver nitric oxide directly to tumors, offering a potential new pathway for brain cancer treatment.
Why it matters
The blood-brain barrier is a major obstacle in treating brain cancer; this discovery could revolutionize drug delivery for previously untreatable tumors.
Despite decades of research, Glioblastoma multiforme (GBM) still remains one of the deadliest types of brain cancers . While treatments including surgery, radiotherapy, and chemotherapy exist and have improved over time, the outcomes for patients remain generally poor. One of the major obstacles to treatment lies in the brain’s natural protection – the blood-brain barrier (BBB) that restricts the passage of anticancer drugs into the tumour.
Recently published research in the scientific journal Oncoscience has sparked some excitement with a unique approach to targeting glioblastoma cells using a novel variant of vitamin B12. While the research is still in its early stages and has not left the preclinical phase yet, it offers a promising new approach to drug delivery in brain tumours.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in